|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Licensing Outlook: A Strategic Guide To Effective Deal-Making And Profitable Partnerships
Business Insights, Aug 2002
Several factors have combined to transform the role of licensing in the pharmaceutical industry - the reconfiguration of the value chain, ongoing global consolidation and M&A and plummeting R&D productivity.
In response, licensing has moved away from its roots as a transaction for intellectual property rights, emerging as a key value driver.
Industry leaders now recognise licensing as a strategic mechanism through which they can achieve their corporate objectives.
The Pharmaceutical Licensing Outlook identifies and examines current best practice in licensing.
Using a blend of market analysis, case studies and executive interviews, the author provides a comprehensive guide to how best to maximize the returns on licensing activity.
Equally valuable for pharmaceutical companies, biotechnology companies and technology providers, this groundbreaking report offers both practical and strategic analysis, including a detailed evaluation of successful deal-making.
Customers who bought this item also bought
Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity
Pharmaceutical Research and Development (R&D) - Increasing Efficiency through Information Technology and Externalization
Innovative R&D Strategies and Models - Outsourcing, Strategic Partnerships and Licensing to Improve Productivity and Contain Costs
Big Pharma’s New Licensing Strategies
Strategies for Building Early-Stage Pharmaceutical Pipelines Through External Sources
Prescription Drugs - Global Strategic Business Report
Drug Discovery Technologies - Global Strategic Business Report
SPECIAL REPORT: Lessons Learned in the Pharma Industry, 2008
A Global Recession Drives New Business Strategies and Evolving Business Models in the Biopharma Industry
How Big Pharma's R&D Focus Is Changing
|
|
|
|
